🇺🇸 FDA
Pipeline program

DNS-6288, DNS-6288

AGP100-C01

Phase 2 small_molecule active

Quick answer

DNS-6288, DNS-6288 for Catecholaminergic Polymorphic Ventricular Tachycardia is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Catecholaminergic Polymorphic Ventricular Tachycardia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials